An Aditum Bio portfolio company, Vitalli Bio was formed in May 2023 following the successful in-licensing of a highly selective dual inhibitor (renamed VIT-801) of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton’s Tyrosine Kinase (BTK) from Daewoong Pharmaceutical Company, for the treatment of a broad range of immunological (autoimmune) disorders. We are advancing the clinical development of VIT-801 and are anticipating beginning the first in-human trials by the fourth quarter 2023.